In patient MR246, who had an FGFR3 S249C-driven bladder cancer that ultimately progressed on erdafitinib, an NF2 frame­shift event was detected by ctDNA together with an FGFR2 V517M mutation. This evidence concerns the gene FGFR3 and urinary bladder cancer.